BioGraphene Announces Publication in Science Advances on Graphene Quantum Dots’ Role Against Inflammatory Response in Colitis

BioGraphene Inc. announced the publication of the journal article titled “Graphene quantum dots as anti-inflammatory therapy for colitis” in Science Advances.

BioGraphene reported graphene quantum dots (GQDs)’ function in treating colitis by exploiting their low toxicity and ease of in vivo clearance. The research employed GQDs through intraperitoneal injection in dextran sulfate sodium–induced chronic and acute colitis model, with validated efficacy. In particular, GQDs effectively prevent tissue degeneration and ameliorate intestinal inflammation by inhibiting TH1/TH17 polarization. Moreover, GQDs switch the polarization of macrophages from classically activated M1 to M2 and enhance intestinal infiltration of regulatory T cells. Therefore, GQDs effectively attenuate excessive inflammation by regulating immune cells, indicating their promise as an alternative therapeutic agent for the treatment of autoimmune disorders, including IBDs.

The published article and findings lend to BioGraphene’s growing body of work around developing novel therapies for neurodegenerative and other CNS diseases.